Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
Corporate culture and the attitude of management might be at the root of the current scandal over serious health damage resulting from the tainting of Kobayashi Kako’s antifungal drug itraconazole with the sleep inducer rilmazafone, believes a health ministry official…
To read the full story
Related Article
- MHLW Urges Drug Makers to Provide Timely, Appropriate Information When Product Shortages Occur
December 22, 2020
- MHLW Urges Drug Makers to Boost Manufacturing Control after Itraconazole Issue
December 15, 2020
- Fukui Pref. Govt Launches On-Site Inspection at Kobayashi Kako over Itraconazole Contaminated with Sleep Inducer
December 11, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
ORGANIZATION
- JPMA Backs Honebuto 2026 Innovation Agenda
July 21, 2026
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
- FIRM Unveils Vision 2030 to Bolster Japan’s Regenerative Medicine Industry
July 15, 2026
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…